ライフサイエンスコーパス: antiphospholipid syndrome

1 mplexes (as would occur in patients with the antiphospholipid syndrome).

2 ipid antibodies present in patients with the antiphospholipid syndrome.

3 ologic findings in patients with established antiphospholipid syndrome.

4 excluded patients with malignant disease and antiphospholipid syndrome.

5 ogenic aPL may be generated in patients with antiphospholipid syndrome.

6 eye is involved frequently in patients with antiphospholipid syndrome.

7 anticoagulant, or a history compatible with antiphospholipid syndrome.

8 , they are useful laboratory markers for the antiphospholipid syndrome.

9 1,633 patients with positive test results of antiphospholipid syndrome.

10 seemed to complicate a diagnosis of primary antiphospholipid syndrome.

11 had serological but no clinical evidence of antiphospholipid syndrome.

12 or ACAs, may also exist in patients with the antiphospholipid syndrome.

13 Splinter hemorrhages can be a feature of the antiphospholipid syndrome.

14 s that together have been referred to as the antiphospholipid syndrome.

15 or thrombosis or other manifestations of the antiphospholipid syndrome.

16 sy specimens from patients with catastrophic antiphospholipid syndrome.

17 specimens from persons who had catastrophic antiphospholipid syndrome.

18 in the vascular lesions associated with the antiphospholipid syndrome.

19 mus in kidney-transplant recipients with the antiphospholipid syndrome.

20 ose with systemic lupus erythematosus and/or antiphospholipid syndrome.

21 nt state in these diseases as well as in the antiphospholipid syndrome.

22 nia, thrombotic thrombocytopenia purpura and antiphospholipid syndrome.

23 dies promote atherosclerosis in persons with antiphospholipid syndrome.

24 a and beta(2)-glycoprotein-I (beta(2)GPI) in antiphospholipid syndrome.

25 new targets for therapeutic intervention in antiphospholipid syndrome.

26 for therapy to prevent pregnancy loss in the antiphospholipid syndrome.

27 contribute to the prothrombotic diathesis in antiphospholipid syndrome.

28 criteria for diagnosis and treatment of the antiphospholipid syndrome.

29 ctively bound IgG derived from patients with antiphospholipid syndrome.

30 re particularly relevant to Ags important in antiphospholipid syndrome.

31 cted at a French referral center for SLE and antiphospholipid syndrome, 24 patients with SLE, with a

32 A high percentage of patients with antiphospholipid syndrome (41%) and systemic lupus eryth

33 Patients with radiologic evidence of antiphospholipid syndrome and no other hypercoagulable s

34 ective and safe alternative in patients with antiphospholipid syndrome and previous venous thromboemb

35 ive immune responses with innate immunity in antiphospholipid syndrome and systemic lupus erythematos

36 s, such as heparin-induced thrombocytopenia, antiphospholipid syndrome and thrombotic thrombocytopeni

37 expansions in JPH3, a fourth patient with an antiphospholipid syndrome, and a fifth patient with B12

38 nts with systemic lupus erythematosus or the antiphospholipid syndrome, and a subset of such antibodi

39 y artery disease, peripheral artery disease, antiphospholipid syndrome, and cancer.

40 rs such as heparin-induced thrombocytopenia, antiphospholipid syndrome, and therapy with asparaginase

41 y complications: a mouse model of obstetrics antiphospholipid syndrome (APS) and a mouse model of pre

42 d with thrombosis in patients diagnosed with antiphospholipid syndrome (APS) and enhance thrombus for

43 Male (NZW x BXSB)F(1) mice develop antiphospholipid syndrome (APS) and proliferative glomer

44 Patients with antiphospholipid syndrome (APS) are at a high risk of de

45 Pregnant women with antiphospholipid syndrome (APS) are at a high risk of ob

46 iphospholipid Abs (aPL) in patients with the antiphospholipid syndrome (APS) bind to the homologous e

47 Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) can be associated with s

48 Xa reactive IgG isolated from patients with antiphospholipid syndrome (APS) display higher avidity b

49 lar weight heparin [LDA+LMWH]) for obstetric antiphospholipid syndrome (APS) does not prevent life-th

50 the pathogenesis, diagnosis and treatment of antiphospholipid syndrome (APS) from current literature.

51 The classification criteria for both SLE and antiphospholipid syndrome (APS) have been updated, and u

52 The antiphospholipid syndrome (APS) is a systemic autoimmune

53 Antiphospholipid syndrome (APS) is an autoimmune disease

54 Antiphospholipid syndrome (APS) is an autoimmune disorde

55 major mechanism of hypercoagulability in the antiphospholipid syndrome (APS) is antiphospholipid Ab-m

56 The antiphospholipid syndrome (APS) is characterized by recu

57 The antiphospholipid syndrome (APS) is characterized by recu

58 Antiphospholipid syndrome (APS) is characterized by recu

59 Antiphospholipid syndrome (APS) is defined by recurrent

60 The antiphospholipid syndrome (APS) is defined by the persis

61 The antiphospholipid syndrome (APS) is defined by thrombosis

62 Antiphospholipid syndrome (APS) is defined by thrombosis

63 r pregnancy loss and either purely obstetric antiphospholipid syndrome (APS) or inherited thrombophil

64 olipid antibodies (aPL) in patients with the antiphospholipid syndrome (APS) recognize a conformation

65 e prothrombotic or proinflammatory status of antiphospholipid syndrome (APS) remain unknown.

66 ibodies test can identify some patients with antiphospholipid syndrome (APS) that are negative for ot

67 for women with the purely obstetric form of antiphospholipid syndrome (APS) treated with prophylacti

68 mmunoglobulin G (IgG) from patients with the antiphospholipid syndrome (APS) upon monocyte activation

69 Women with antiphospholipid syndrome (APS), a condition characteriz

70 In the antiphospholipid syndrome (APS), antiphospholipid Abs (a

71 In antiphospholipid syndrome (APS), antiphospholipid antibo

72 e clinical phenotype, including catastrophic antiphospholipid syndrome (APS), atypical presentations

73 linked to autoimmune disorders, particularly antiphospholipid syndrome (APS), in which autoantibodies

74 sis and thrombocytopenia are features of the antiphospholipid syndrome (APS), suggesting that antipho

75 ctly contribute to hypercoagulability in the antiphospholipid syndrome (APS).

76 Ab (aPL) and thrombosis is recognized as the antiphospholipid syndrome (APS).

77 )GPI) appear to be a critical feature of the antiphospholipid syndrome (APS).

78 b (aCL), and thrombosis is recognized as the antiphospholipid syndrome (APS).

79 manifestations is now well-recognized as the antiphospholipid syndrome (APS).

80 with systemic lupus erythematosus or primary antiphospholipid syndrome (APS).

81 (designated IS6) from a patient with primary antiphospholipid syndrome (APS).

82 th recurrent thrombosis in patients with the antiphospholipid syndrome (APS).

83 thrombosis are frequent complications of the antiphospholipid syndrome (APS).

84 the effect of antibodies from patients with antiphospholipid syndrome (APS).

85 patients with non-criteria manifestations of antiphospholipid syndrome (APS).

86 ribute to thrombosis and miscarriages in the antiphospholipid syndrome (APS).

87 e the mid-1980s for diagnosing patients with antiphospholipid syndrome (APS).

88 y with antiphospholipid antibodies is termed antiphospholipid syndrome (APS).

89 to promote thrombosis and fetal loss in the antiphospholipid syndrome (APS).

90 IgG anti-tPA antibodies in patients with the antiphospholipid syndrome (APS).

91 ) is the most common disease associated with antiphospholipid syndrome (APS).

92 s positively correlated with the symptoms of antiphospholipid syndromes (APS), including thrombosis a

93 ere treated with IgG aPL (from patients with antiphospholipid syndrome [APS]) or with control IgG (fr

94 otic mechanisms, women with purely obstetric antiphospholipid syndrome are at risk for thrombotic com

95 ations of this findings in patients with the antiphospholipid syndrome are discussed.

96 pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate ther

97 ts with systemic lupus erythematosus and the antiphospholipid syndrome, are associated with adverse p

98 lar risks, lupus nephritis, CNS disease, the antiphospholipid syndrome, assessment of disease activit

99 roquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestat

100 ay hold promise as a therapeutic approach to antiphospholipid syndrome-associated pregnancy complicat

101 ndrome patient sera are not only a marker of antiphospholipid syndrome but are directly involved in t

102 Catastrophic antiphospholipid syndrome (CAPS) is a potentially lethal

103 Catastrophic antiphospholipid syndrome (CAPS) is characterized by his

104 The catastrophic antiphospholipid syndrome (CAPS) is rare and usually fat

105 is is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are

106 dies purified from the sera of patients with antiphospholipid syndrome complicated by thrombosis grea

107 NT FINDINGS: Although the pathophysiology of antiphospholipid syndrome continues to be poorly underst

108 the antibodies and antigens involved in the antiphospholipid syndrome has provided many new insights

109 me that involves the injection of high-titer antiphospholipid syndrome human serum, complement activa

110 munoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hy

111 e either purified IgG from patients with the antiphospholipid syndrome (IgG-APS) or normal IgG from h

112 G (IgG) isolated from either a patient with antiphospholipid syndrome (IgG-APS), a healthy control s

113 primarily on the spectrum and management of antiphospholipid syndrome in children; this review summa

114 hile the 956A allele was associated with the antiphospholipid syndrome in patients with SLE (P = 0.00

115 s in the glomeruli, recapitulating the human antiphospholipid syndrome in these mice.

116 Vascular complications of antiphospholipid syndrome include serious and life-threa

117 controversial issues in the treatment of the antiphospholipid syndrome include the use of less intens

118 Antiphospholipid syndrome includes elevation of either t

119 The antiphospholipid syndrome is a disorder of recurrent thr

120 The antiphospholipid syndrome is a major feature of systemic

121 PURPOSE OF REVIEW: Antiphospholipid syndrome is a rare cause of ocular vaso

122 The antiphospholipid syndrome is a thrombophilic condition m

123 Antiphospholipid syndrome is an autoimmune disease chara

124 Antiphospholipid syndrome is characterized by recurrent

125 The antiphospholipid syndrome is characterized by thrombosis

126 Antiphospholipid syndrome is characterized by thrombosis

127 Antiphospholipid syndrome is characterized by thrombosis

128 The antiphospholipid syndrome is characterized clinically by

129 Diagnosis and treatment of antiphospholipid syndrome is difficult, however, because

130 f thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain.

131 m, but whether it is useful in patients with antiphospholipid syndrome is uncertain.

132 ct (MAb 519) and from a patient with primary antiphospholipid syndrome (MAb 516).

133 ate clinical manifestations in patients with antiphospholipid syndrome may be established.

134 f the thrombin-reactive aCL in patients with antiphospholipid syndrome may bind to PC and APC.

135 n (n = 3), and celiac occlusion secondary to antiphospholipid syndrome (n = 1).

136 rating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications

137 Patients with antiphospholipid syndrome nephropathy who required trans

138 essels of patients with primary or secondary antiphospholipid syndrome nephropathy.

139 by The Nimes Obstetricians and Hematologists-Antiphospholipid Syndrome (NOH-APS) Study Group give us

140 related to systemic lupus erythematosus and antiphospholipid syndrome occur in association with mult

141 that anti-beta(2)-GP1 IgG autoantibodies in antiphospholipid syndrome patient sera are not only a ma

142 anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient.

143 anticoagulation are similarly protective in antiphospholipid syndrome patients after the first throm

144 Catastrophic antiphospholipid syndrome patients usually receive a com

145 r subsets of antiphospholipid Abs present in antiphospholipid syndrome patients.

146 stemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (primary APS) undergoing OI/IV

147 rs, such as rheumatoid arthritis and primary antiphospholipid syndrome, reacted infrequently.

148 Pregnancy complicated by antiphospholipid syndrome requires expert care and a tea

149 ative colitis, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren syndrome, myasthenia

150 cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the p

151 In the mouse model of antiphospholipid syndrome that involves the injection of

152 th the spectrum of clinical manifestation of antiphospholipid syndrome, the diagnostic criteria of th

153 n documented as a biomarker for diagnosis of antiphospholipid syndrome, their direct role in the path

154 of the immunology and pathophysiology of the antiphospholipid syndrome, treating this condition remai

155 f polyclonal IgG purified from patients with antiphospholipid syndrome, using both solid-phase and fl

156 a(2)-GP1 autoantibodies from 3 patients with antiphospholipid syndrome were affinity-purified using h

157 in two UK hospitals, included patients with antiphospholipid syndrome who were taking warfarin for p